A novel generation of drugs is introduced in the treatment of heart failure (HF). These drugs, including phosphodiesterase-5 inhibitors, guanylate cyclase stimulators and activators, share the feature that their action is either endothelial-mediated or substitutes for endothelial pathways, in particular the nitric oxide-cyclic guanosine monophosphate pathway, thereby influencing homeostatic balances in virtually each organ system in a pleiotropic fashion. Unfortunately, recent clinical trials with some of these drugs have shown disappointing results, at least in the setting of HF with a preserved ejection fraction. This suggests that their clinical use may require approaches that diverge from traditional pharmacological approaches, the latter often titrated on the effects of drugs on haemodynamic parameters or single biomarkers. In this paper we preconize that HF drugs with an endothelial profile should be applied conform to principles of endothelial physiology and systems pharmacology. This type of drug therapy should be viewed as a systems physio-pharmacological intervention and its clinical use accustomed to systems pharmacological principles, comparable to the systemic endothelial-mediated benefits induced by exercise training in HF. We will review the actions of these drugs and define criteria to which trials with these drugs should comply in order to increase chances of success.
Introduction
During the past 35 years, landmark randomized trials have demonstrated an improvement in the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF), with benefits resulting from agents interfering with the renin-angiotensin-aldosterone as well as the adrenergic nervous system. However, hospital readmissions remain high and there still is no cure. 1 We have witnessed the introduction of a new generation of drugs in patients with HF, including serelaxin, sildenafil and other phosphodiesterase-5 (PDE5) inhibitors, neutral endopeptidase inhibitors, guanylate cyclase stimulators and activators, neuregulin-1, natriuretic peptides, myosin activators, mitochondria protectants, and heart rate slowing agents. Many of these novel drugs share the feature that their action is either endothelium-mediated or substitutes for endothelial * pathways, in particular the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway. 2 These drugs open a new conceptual avenue in the pharmacological treatment of HF. Unfortunately, recent clinical trials with some of these drugs have shown disappointing results, 3, 4 at least in the setting of HF with a preserved ejection fraction (HFpEF). Although there are probably multiple reasons for these disappointing results, these trials demonstrate that the clinical introduction of drugs whose mode of action is predominantly explained by activation of endothelial pathways may be more challenging than originally anticipated, and may require approaches that differ from traditional pharmacological ones.
We preconize that drugs with a predominant endothelial profile will improve overall homeostasis and outcomes in HF provided that their application conforms to the basic principles of endothelial physiology, and hence are allowed to develop pleiotropic actions throughout the body. Perhaps, the basic rules for applying these drugs clinically can be derived from the principles of exercise training therapy. We suggest that exercise is the most genuine way to preserve and activate the endothelial system and to restore overall body homeostasis and health. In this paper, we present pharmacological endothelial activation as a systems physio-pharmacological intervention and define some criteria to which clinical trials with such drugs may have to comply in order to increase chances of success. This is not a classical review in which we limit ourselves to discussing scientific facts, but a conceptual paper in which we present novel hypotheses ( Table 1 ).
The endothelial system
Because of its unique position at the interface between the individual organs and the circulating blood the endothelial system is, despite some vascular bed-specific heterogeneity, well-placed in stabilizing overall homeostasis by simultaneously affecting all organ functions in the body. 5 The key role of the endothelial system has been generally well recognized in macro-and micro-resistance vessels of most organs, where endothelial cells interact with subjacent smooth muscle cells, thereby controlling vasomotricity, and hence perfusion to the organs. More important but less well studied, however, are endothelial cells in capillaries, which constitute with approximately 85% the largest endothelial surface in each organ. In capillaries, endothelial cells directly communicate with subjacent organ and tissue cells, 5, 6 such as neurons in the brain, 7 16, 17 have proposed a concept indicating that endothelial dysfunction is more important in HFpEF than in HFrEF, numerous studies have demonstrated that in HF, regardless of ejection fraction (EF), the entire cardiovascular endothelial system has become significantly dysfunctional. 18, 19 Accordingly, because of the stabilizing role of the endothelial system at the interface between plasma and subjacent tissue cells, interventions that improve or replace endothelial function would be expected to act as a major driving force in orchestrating the normalization of cardiovascular homeostasis of all body organs and systems. 20 This will result in improved organ perfusion and correction of the haemodynamic mismatch between the left ventricle and the right ventricle with the systemic and pulmonary arterial systems, respectively, and optimize the endothelial cell-to-cell communication with subjacent renal, muscular, liver, gastro-intestinal, and cerebral organ cells.
Exercise training activates the endothelium and acts as a systems physio-pharmacological intervention
Probably the most valid way to activate or restore endothelial pathways is exercise training, 21, 22 a therapeutic intervention with benefits on prognosis, quality of life, and frequency of hospitalization. In the HF-ACTION trial, 23 for highly prognostic predictors, exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or hospitalization because of HF. 23 In a recent Cochrane systematic review that included 33 trials with 4740 patients predominantly with HFREF and New York Heart Association (NYHA) classes II and III, there was no difference in pooled mortality between exercise-based rehabilitation vs. no exercise control, at least in trials with up to 1-year of follow-up. 24 However, there was a trend towards a reduction in mortality with exercise in trials with more than 1 year of follow-up. Compared with control, exercise training reduced the rate of overall and HF-specific hospitalization and exercise also resulted in a clinically important improvement in the Minnesota Living with Heart Failure questionnaire. 24 Features of exercise training therapy in HF may serve as a strategic guide for testing some of the novel generation of drugs in clinical trials. Exercise training therapy has become a well-established recommendation in the management of patients with HF. 25 -29 Best tolerated and most successful are 3-4 weekly exercise training therapeutic programs with a very slow and gentle onset, gradually increasing in duration and intensity under strict medical monitoring over a period of about 3-4 months, and continued thereafter with three to four 1-hour training sessions per week. Wisloff and co-workers 30 experimented with intensified training programmes in HF patients ('aerobic interval training, three times per week up to 95% of peak heart rate instead of 70% of peak heart rate) and showed that effects on VO 2 max and left ventricular (LV) remodelling became larger. 30 However, this trial was small (n = 27 patients) and effects on mortality have not been tested.
Intriguingly, the principles of above intermittent and appropriately gauged exercise training therapy profoundly differ from principles of contemporary pharmacology, the latter aiming at rapid uptitration of uninterrupted dosing regimens and stable drug plasma concentrations. The beneficial effects of exercise training therapy have been ascribed to an improved physiological homeostasis of all organ functions, resulting from a balanced activation of the various body systems acting in parallel: i.e. the cardiovascular, the neuro-hormonal, 31 the endocrine, the immunological, and more recently the endothelial system ( Figure 1 ). 5 Improvement of endothelial function has been shown to play a central role in integrating and coordinating the exercise-induced beneficial effects, i.p. in re-establishing organ homeostasis. Factors that may contribute to this improvement are shear stress-activation of endothelial cells as well as various exercise-induced plasma constituents which may affect endothelial function (e.g. metabolites, hormones, stressors, free radicals, and miRNAs). Furthermore, exercise training improves endothelial progenitor cell number and function. 32 Improvement of capillary endothelial function will guide normalization of overall homeostasis by: (i) normalizing the complex cell-to-cell communication between endothelial cells and subjacent organ and tissue cells (Figure 2) , involving different interacting and interdependent paracrine pathways acting in parallel, in particular the NO pathway, the endothelin-1 pathway, the neuregulin-1 pathway, 33 the prostacyclin pathway, the vascular endothelial growth factor pathway and the NOX pathway; (ii) optimizing some vital endothelial (enzymatic) activities, • Exercise therapy improves the function of virtually every organ
• Benefits of exercise therapy in heart failure result from convergent pleiotropic amplification of all organ functions mediated and coordinated through improved endothelial function
• Exercise therapy improves a wide range of chronic diseases
• Drug therapy can be designed according to principles of exercise therapy (gentle, intermittent, and slowly uptitrated)
• Principles of exercise therapy profoundly differ from the principles of contemporary pharmacology
• Future pharmacological heart failure trials should not target one pathway or biomarker, but be designed to allow slow improvements of homeostasis
• Exercise therapy improves endothelial function
• Clinical use of new-generation drugs with endothelial action should take into account basic principles of endothelial physiology and of exercise therapy
• The endothelium communicates with virtually every tissue cell in the body • Paracrine endothelial function results from many interdependent pathways, not just from nitric oxide alone • New-generation heart failure drugs improve or mimic endothelial function, but usually change only one of the endothelial pathways • Introduction of these drugs into clinical practice has been more difficult than anticipated, with several failed clinical trials in particular those dependent of angiotensin-converting enzyme, carbonic anhydrase-4, von Willebrand factor, cyclooxygenase 1 and 2, oestrogen receptor signaling, 34 neutral endopeptidase, natriuretic peptides, platelet endothelial cell adhesion molecule (PECAM-1) and dipeptidyl peptidase IV; 35 (iii) normalizing, clearing and metabolic processing by the endothelial cells of various plasma constituents; 36 and (iv) by counteracting the endothelial inflammasome as well as optimizing the plasma oxidant-antioxidant balance.
Accordingly, from a pharmacological point of view, exercise training therapy in HF seems to resemble the ideal endotheliummediated drug with pleiotropic activity (i.e. by orchestrating the improvement of the homeostasis of all body organ functions). Alternatively, from a physiological point of view, the beneficial effects of exercise training on organ function could be viewed as a systems biological or systems pharmacological intervention. Being complementary to one another, both the pleiotropic and the systems pharmacological views may contribute equally to the re-establishment of overall body homeostasis during exercise training in patients with HF. Indeed, the HF syndrome is the clinical manifestation of failing complexity involving most body organs and systems. It is not the mere result of a failing single organ, cell, molecule, or gene. The connotation of physio-pharmacology systems is, therefore, most appropriate to describe the therapeutic effect of exercise training at all hierarchical scales in each of the body systems from intracellular, cellular, tissue, organ, overall organism, patient's pathophenotype, and diseasome. drugs and launching appropriate clinical trials for the treatment of HF? By taking into account lessons learned from the beneficial pleiotropic effects of exercise training in HF, hence by gently and progressively targeting homeostasis rather than focusing on the pharmacological effects on single biomarkers, 38 future clinical trials in HF may acquire additional physiological elegance and credibility. A gentle and well-dosed systems physio-pharmacological approach, similar to the approach used during exercise training therapy may, therefore, be a fresh concept for designing future HF clinical trials with the novel drugs acting primarily on the endothelium and the NO-cGMP pathway. The negative results observed in some recent clinical trials with some of these drugs, following significant initial successes in the earlier trials, can perhaps be explained by the fact that these principles have been insufficiently well-regarded. 39, 40 In the 1980s to 1990s, clinical trials in HF were successfully launched based on the adagio one-target-one-response of contemporary pharmacology leading to the successes with angiotensin-converting enzyme (ACE) inhibitors, beta-1 receptor antagonists, and aldosterone receptor antagonists. However, it is currently believed, that the success of this triad of drugs in the treatment of HF results from their pleiotropic actions as much as from inhibiting the original single enzyme or receptor target or biomarker. Management of HF has been designed to target one mechanism almost exclusively and, historically, cardiomyocytes, inotropy and EF, were the most popular 'low-hanging fruit' targets. The heart is, however, a pluricellular organ consisting of interacting and interdependent 41, 42 Figure 1 The pleiotropy of exercise. Exercise training is the most potent medicine known to man. Beneficial effects of physical activity have been demonstrated in virtually all organ systems, including the cardiovascular system, the renal system, the liver, skeletal muscle, metabolism, immune system, respiratory system, and neuronal system, orchestrating the homeostasis of all organ functions. Beneficial effects of physical activity in clinical medicine have been documented both in primary prevention and in numerous chronic diseases including heart failure, arterial hypertension, atherosclerosis, metabolic syndromes such as diabetes, chronic kidney failure, fatty liver disease, chronic obstructive pulmonary disease (COPD) and pulmonary hypertension, and mental and neurodegenerative diseases. 23,26 -29,66,94-101 Exercise training also improves the function of the endothelial system. Accordingly, the endothelial actions may be vital to integrate the exercise-induced beneficial effects. In the capillaries especially, endothelial cells directly influence tissue cells through the release of interdependent paracrine substances. LV, left ventricular.
inflammatory cells, and, most importantly, endothelial cells. 5, 45, 46 Moreover, in addition to eliciting unanticipated beneficial effects in non-cardiomyocytes in the heart, these drugs also elicit effects in other organs such as the kidney and the brain, thereby resembling typical network behaviour. Hence, the connotation of physio-pharmacology systems was launched by some as a more appropriate term in describing the beneficial effects of these drugs, and as the optimal way of treating complex diseases such as HF.
New ideas for designing future clinical trials in heart failure
The pivotal role of a dysfunctional endothelial system in the pathogenesis of HF has been demonstrated in several studies. potential therapeutic target during the very early phases of HF. 48 -52 We have recently witnessed the introduction of novel molecules that could either normalize endothelial function or substitute for some of the endothelial-mediated pathways, in particular the NO-cGMP pathway. Based on the pivotal role of the endothelial system in orchestrating the physio-pharmacological system's benefits of exercise training in patients with HF, designing future clinical trials with a new generation of drugs with a predominant endothelial activity may benefit from a physio-pharmacological systems strategy while taking into account endothelial physiology. From this, a couple general physiological principles lead to some practical recommendations, summarized in Table 2 . These recommendations relate to the action of the drug, the characteristics of the patients to be treated with the drug, the dosing regimen and the trial design, including the choice of trial end-points, intermediate analyses beyond mortality and exercise tolerance, and identification of responders and non-responders.
Figure 2
The endothelium is a sensor for various biological stimuli and acts as an effector on neighbouring organ cells. Endothelial cells have a sensing function to detect changes in haemodynamic, chemical, neurohormonal, and mechanical stimuli. Shear stress is an important stimulus in arteries and larger arterioles. Endothelial cells in specific microcirculations such as the heart or skeletal muscle are subjected to mechanical stress such as cyclical stretching and compression, and load-dependent strain. Furthermore, all endothelial cells have receptors for metabolites, neurohormonal factors, cytokines, and growth factors. Secreted angiocrine substances constitute the endothelial effector function of the myocardium, these include small molecules, peptides, proteins, microvesicles, and microRNAs. ACE, angiotensin-converting enzyme; ADP, adenosine diphosphate; ANP, atrial natriuretic peptide; CGRP, calcitonin gene-related peptide; CNS, central nervous system; COX, cyclooxygenase; CTGF, connective tissue growth factor; DKK3, Dickkopf-related protein 3; FGF-2, fibroblast growth factor-2; FST, follistatin; IL-1, interleukin-1; NEP, neutral endopeptidase; NO, nitric oxide; NOX, NADPH-oxidase family; 102,103 PDGF, platelet-derived growth factor; PECAM, platelet endothelial cell adhesion molecule; ROS, reactive oxygen species; TGF , transforming growth factor beta; TNF , tumour necrosis factor alpha; TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor. We have recently hypothesized that drugs with a predominant endothelial activity may require prolonged exposure at very low dosages, even if at first no measurable changes are observed. 2 As various signalling events between the endothelium and subjacent organ cells are interdependent and balanced, one may expect a mismatch in these events in patients with HF. This mismatch may be further hampered if only one of these pathways, for example, either the NO-cGMP pathway or the brain natriuretic peptide-cGMP pathway, or the NRG-1/ErbB pathway, or the endothelin-1/ET-A receptor pathway would be targeted by high doses of such a drug. In contrast, a low dosage is expected to re-establish a balanced crosstalk between the ventricles and the pulmonary and systemic circulation.
For example, in HF patients with concomitant pulmonary hypertension and right ventricle-pulmonary artery mismatch, chronic exposure to lower dosages of drugs that activate the endothelial NO-sGMP pathway would allow for a gentle, auto-amplifying shear stress-induced and endothelial-mediated haemodynamic normalization to a low impedance/high capacitance pulmonary vascular system, while avoiding sudden unwanted drop in left atrial preload. Similarly, in the resistive systemic circulation, as most of these drugs are vasodilators, focus in HF patients should instead be on modulating systemic arterial impedance while avoiding an unwanted arterial pressure drop. Therefore, both in the systemic and pulmonary circulations, a prolonged exposure (in terms of months) at low dosages of these 'endothelial . drugs' should aim at correcting any LV-arterial mismatch while maintaining arterial perfusion pressure within physiological limits. Furthermore, prolonged exposure to low dosages of drugs with a predominant endothelial and NO-cGMP stimulating activity are expected to re-establish a balanced ventricular-arterial coupling by modulating timing and rate of LV relaxation, both directly through endothelium-mediated effects on onset and rate of relaxation of the cardiomyocytes and indirectly by subtle changes in arterial impedance resulting in shifts in timing of incoming reflected waves, hence of the loading sequence during LV systole. As a result, a dosed reverse cardiac and vascular remodelling will ensue. Even in the absence of any immediate and manifest peak haemodynamic effect, progressive and subtle drug-induced changes at low dosages may be estimated and gauged by measuring ventricular time intervals, in particular shifts in the time sequence of the ventricular loading conditions caused by time shifts of the returning reflected waves from early to late systole. Neglecting these basic physiological rules by applying high, 'pharmacologically active' dosages and measuring only static peak haemodynamic variables will provide misleading information. 53 -55 It is like neglecting the lessons learned from the above exercise training programmes and abruptly imposing an exercise training programme consisting of ever-repeating 100-m runs on a patient with HF.
In peripheral organs, such as the kidneys, liver, gastro-intestinal tract, skeletal muscle, and brain, drugs with a predominant endothelial activity will affect organ function in two ways: (i) indirectly, by increasing organ perfusion through the relaxing effects of endothelium on vascular smooth muscle; and (ii), much more importantly, through direct cell-to-cell communication between capillary endothelial cells and subjacent organ cells (e.g. alveolar epithelial cells, glomerular and tubular epithelial cells, hepatocytes or neurons), resulting in improved renal function, gauging and optimizing the cardiac-renal axis, exercise tolerance, brain cognitive function, and organ homeostasis in general.
Clinical assessment of endothelial dysfunction
Given its pathophysiological importance and the emerging pharmacological tools to target endothelial dysfunction, clinical assessment of endothelial function would be useful ( Table 3 ). Monitoring endothelial function may be of great value in staging the disease, establishing the direct endothelial efficacy of a drug, and for individualized patient selection. Endothelial functional tests should be safe, non-invasive, reproducible, cheap and standardized. In addition, the results should allow a broad appreciation of the numerous functions of the endothelium, not merely reflecting the integrity of one pathway (e.g. the NO-cGMP pathway) or of one process (e.g. the regulation of vascular tone). Ideally, endothelial tests should discriminate between endothelial function in different organ beds (e. glomerular capillaries, blood-brain barrier, or resistance vessels). Indeed, it is to be expected that endothelial dysfunction does not uniformly deteriorate throughout the body during the natural history of a disease and may show inter-individual variability. Unfortunately, no single test fulfils these requirements and endothelial tests still have a limited role in individual clinical decision-making. We refer the reader to a number of excellent publications reviewing the currently available tests of endothelial function. 56 -59 Clinical endothelial function tests currently have no role in the assessment of individual patients and in individual clinical decision-making, and have seldom been used in clinical trials, mostly owing to biological and assay variability of the results. While endothelial tests are still too difficult, expensive and variable for clinical use, endothelial testing should nevertheless be further explored with the purpose of (i) stratifying populations with regard to the importance of endothelial dysfunction in the pathophysiology of disease, (ii) helping to select drugs in early proof-of-concept trials and dose finding studies, and (iii) helping to predict therapeutic response.
Endothelial effects of drugs used in heart failure
A substantial number of drugs, applied as a treatment of HF, has been shown to influence endothelial function or to mimic the function of one or more endothelial factors. Some of these drugs have been designed and/or developed based on the knowledge of endothelial physiology (e.g. endothelin receptor antagonists, PDE5 inhibitors, NO-donors, neuregulin-1, and direct soluble guanylate cyclase stimulators). Table 4 summarizes the most interesting clinical trials that have been performed with such drugs. Other drugs were not originally designed to modify or restore endothelial function, but appeared to have a direct or indirect influence on the endothelium during subsequent analysis. In Table 5 we summarize evidence for indirect endothelial activity of mineralocorticoid receptor antagonists, ACE inhibitors, angiotensin receptor antagonists, statins, and xanthine oxidase inhibitors. NO, nitric oxide; NYHA, New York Heart Association; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; RR, relative risk; PDE5, phosphodiesterase 5; cGMP, cyclic guanosine monophosphate; HT, hypertension; PAPs, pulmonary arterial pressure in systole, PAWP, pulmonary arterial wedge pressure; RV, right ventricular; ET, endothelin; LV, left ventricular; AHF, acute heart failure; ISDN, isosorbide dinitrate; ISMN, isosorbide mononitrate. 84, 85 Xanthine oxidase inhibition Allopurinol improves endothelial function and reduces markers of oxidative stress in HFrEF patients 86, 87 L-Arginine and L-citrulline L-Arginine and L-citrulline supplementation improved endothelial function in HFrEF patients 88, 89 Cocoa Flavanol-rich chocolate improves endothelial function in HFrEF patients 90 Dietary nitrate Acute intake of beetroot juice increases NO bioavailability, and increased exercise capacity in HFpEF patients 91 -93 FMD, flow-mediated dilation; HF, heart failure; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; EPC, endothelial progenitor cell; HFrEF, heart failure with reduced ejection fraction; NO, nitric oxide; HFpEF, heart failure with preserved ejection fraction.
deficit in HF. To our knowledge, and surprisingly, these agents have not been clinically investigated as to their effect on endothelial function. Dose selection for future HF outcome trials was based only on the effects on N-terminal pro-brain natriuretic peptide (NT-proBNP). 61 In SOCRATES-REDUCED 62 compared with placebo in HFrEF patients, the pooled vericiguat group (daily target doses of oral vericiguat 1.25 mg, 2.5 mg, 5 mg, and 10 mg) did not have a statistically significant effect on change in NT-proBNP level at 12 weeks. 62 Nevertheless, based on the results of an exploratory secondary analysis, suggesting a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level, the investigators called for further trials, probably with the highest tested dose of 10 mg, which was well tolerated. Following the reasoning in the present paper, we would recommend low dosages, too low to affect haemodynamic parameters acutely, sustained for prolonged periods to allow homeostatic adaptations in all organs to conform to the principles of physical rehabilitation and exercise programmes. Furthermore, we would recommend including measurements of endothelial function (Table 3 ) instead of relying only on measurements of circulating biomarkers.
Conclusion
Pharmacologically enhancing or protecting endothelial activity is a fascinating and likely powerful new tool in the treatment of HF. It has the potential to orchestrate the normalization of cardiovascular homeostasis of all body organs and systems, in a manner similar to exercise therapy-induced effects on endothelial function. As such, we hypothesize that introducing drugs with a predominant endothelial activity in clinical practice should be based on basic principles of endothelial physiology and its use adapted to principles of systems pharmacology in order to increase the chances of success. This paper is intended to summarize these principles.
. We hope it may serve as a guide for further clinical development of endothelial drug therapy, and for pleiotropic therapy in HF in general.
